Literature DB >> 17194969

[Prevalence of diabetes-related autoantibodies in celiac disease].

L Laadhar1, M Ben Hariz, M Zitouni, M Sellami-Kallel, A Toumi, A Mehrezi, S Makni.   

Abstract

THE AIM: of this study is to investigate the prevalence of diabetes-related autoantibodies in a group of children with celiac disease and to compare it with a control group.
MATERIAL AND METHODS: We recruited 31 celiac children at diagnosis (on gluten containing diet) and 31 age and sex matched healthy children. Anti-islet cell antibodies (ICA) were detected by indirect immunofluorescence on monkey pancreas. Anti-glutamate decarboxylase (anti-GAD) and anti-tyrosine phosphatase (anti-IA2) antibodies were assessed by a radio-immuno- precipitation method.
RESULTS: Three out of 31 celiac patients (9.7%) had one or more diabetes-related autoantibodies. ICA, anti-GAD and anti-IA2 were found in respectively 3.2%; 3.2% and 9.7% of patients. Only one control (3.2%) had anti-GAD. There was no statistically significant difference between the 2 groups.
CONCLUSION: The risk to develop diabetes seems to be the same in celiac patients and in healthy subjects thus screening of diabetes-related autoantibodies is not justified in celiac patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17194969     DOI: 10.1016/s0003-4266(06)73011-6

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  2 in total

1.  Autoantibody frequency in celiac disease.

Authors:  Erkan Caglar; Serdal Ugurlu; Aliye Ozenoglu; Gunay Can; Pinar Kadioglu; Ahmet Dobrucali
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

2.  Beta-cell autoimmunity in pediatric celiac disease: the case for routine screening?

Authors:  Giuseppe d'Annunzio; Alessandro Giannattasio; Elena Poggi; Emanuela Castellano; Angela Calvi; Angela Pistorio; Arrigo Barabino; Renata Lorini
Journal:  Diabetes Care       Date:  2008-11-18       Impact factor: 19.112

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.